A self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite and its preparation method and application

By developing a self-oxygen-targeted bionic nuclear membrane structure nanocomplex, using the bionic lipid membrane and hollow MnO2 nuclear membrane structure to generate oxygen at the tumor site, the problem of poor clearance and targeting of traditional nano drugs in the liver is solved. It has achieved targeted tumor delivery and improved efficacy, and has a variety of therapeutic properties.

CN114177309BActive Publication Date: 2024-11-26AFFILIATED PEOPLES HOSPITAL OF NINGBO UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111293490.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-11-03
Publication Date
2024-11-26
Estimated Expiration
2041-11-03

AI Technical Summary

Technical Problem

Traditional nanomedical targeting strategies have poor results in liver clearance and targeting, and complex ligand modification technology, which makes it difficult to effectively improve the tumor hypoxic environment, limiting the efficacy of tumor treatment.

Method used

Develop a self-oxygen-targeted bionic nuclear membrane structure nanocomplex, which contains a bionic lipid membrane and a hollow MnO2 nuclear membrane structure, carries chemotherapy drugs, has tumor cell membrane protein modification and photosensitizer, which can produce oxygen in the tumor site. Improve the hypoxic environment and achieve targeted delivery.

Benefits of technology

It has achieved targeted tumor delivery, improved hypoxia environment, enhanced therapeutic efficacy, and has MRI imaging, photothermal and photodynamic therapeutic properties, improving the biocompatibility and targeting effect of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114177309B_ABST
    Figure CN114177309B_ABST
Patent Text Reader

Abstract

The present invention provides a self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite and a preparation method and application thereof, wherein the nanocomposite comprises a nuclear membrane structure comprising a bionic lipid membrane and a hollow MnO2; the bionic lipid membrane is a phospholipid bimolecular membrane whose surface is modified with tumor cell membrane proteins; the hollow MnO2 is used to load tumor therapeutic drugs, and the drug is at least one of a chemotherapy drug and an immunotherapy drug; one of the inventive objects of the present invention is to provide a self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite that can be used for magnetic resonance imaging, fluorescence imaging, tumor chemotherapy and phototherapy; the second object of the present invention is to provide a preparation method of the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of drug carriers, and in particular to a self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite and a preparation method and application thereof. Background Art

[0002] The traditional nanomedicine targeting strategy consists of two steps: first, the surface of the nanoparticles is modified with polyethylene glycol to escape clearance by the reticuloendothelial system; then, ligand modification is performed to obtain targeting ability. However, recent studies have shown that nanomedicines modified with polyethylene glycol are rapidly cleared by the liver after continuous administration, while the ligand modification technology is cumbersome and has problems such as insufficient modification breadth. Therefore, the actual targeting effect in vivo is often unsatisfactory.

[0003] Tumor hypoxia microenvironment is closely related to the occurrence and development of tumors and is a huge challenge in tumor treatment. Tumor hypoxia can lead to various treatment resistances, greatly limiting the efficacy of tumor treatment. Therefore, finding a suitable strategy to improve tumor hypoxia is crucial to improving the efficacy of tumor treatment. At present, the strategies to improve tumor hypoxia mainly include hypoxia improvement based on tumor vascular normalization, hypoxia improvement based on artificial oxygen supply carriers, and hypoxia improvement based on in situ tumor oxygen production. Summary of the invention

[0004] One of the inventive objectives of the present invention is to provide a self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite that can be used for magnetic resonance imaging, fluorescence imaging, tumor chemotherapy and phototherapy.

[0005] In order to solve the above-mentioned purpose of the invention, the present invention provides a self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite, wherein the nanocomposite includes a nuclear membrane structure of a bionic lipid membrane and a hollow MnO2; the bionic lipid membrane is a phospholipid bilayer membrane with a surface modified with tumor cell membrane proteins; the hollow MnO2 is used to load tumor therapeutic drugs, and the drug is at least one of a chemotherapy drug and an immunotherapy drug.

[0006] Optionally, the biomimetic lipid membrane contains a photosensitizer, and the photosensitizer is at least one of dihydrochlorin e6 (Ce6), ICG-ODA, ICG-NH2, ICG-COOH, ICG-NHS, ICG-MAL, ICG-SH, ICG-N3, ICG-ALK, ICG-Biotin, IR780 and IR783 or IR808.

[0007] Optionally, the hollow MnO 2 The mass ratio is 30% to 80%. Further optionally, the hollow MnO 2The mass percentage is selected from 80%, 75%, 70%, 65%, 60%, 55%, 50%, 30%, 35%, 40%, and 45%.

[0008] Optionally, the hollow MnO 2 The specific surface area is 60~200m 2 / g, the average pore size is 1.5-10nm, and the mesoporous surface is disordered.

[0009] Further optionally, the hollow MnO 2 The specific surface area is selected from 200m 2 / g, 180m 2 / g, 160m 2 / g, 140m 2 / g, 60m 2 / g, 80m 2 / g、100m 2 / g, 120m 2 / g.

[0010] Optionally, the hollow MnO 2 The particle size is 50-150 nm, and the pore size is 2-10 nm; it has good drug loading capacity.

[0011] Optionally, the phospholipid bilayer membrane includes lecithin, hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, dipalmitoyl phosphatidylethanol, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylethanolamine, polyethylene glycol-distearoyl phosphatidylethanolamine, 1,2-dipalmitoyl-sn-glyceryl-3-phosphatidic acid glyceryl-sodium salt, 1,2-distearoyl-sn-glyceryl-3-phosphatidylcholine, 1,2-dipalmitoyl-sn-glyceryl-3-phosphatidic acid-sodium salt and 1,2-dipalmitoyl-sn-glyceryl-3-phosphatidylcholine.

[0012] Optionally, the cancer includes breast cancer, thyroid cancer, pancreatic cancer, lung cancer, kidney cancer, liver cancer and melanoma.

[0013] Optionally, the photosensitizer is an indole cyanine dye, which includes a lipophilic derivative of ICG such as ICG-ODA, ICG-NH2, ICG-COOH, ICG-NHS, ICG-MAL, ICG-SH, ICG-N3, ICG-ALK, ICG-Biotin, IR780, IR783, IR808 or a mixture of two or more of dihydrochlorin e6.

[0014] Optionally, the chemotherapy drug is selected from at least one of anthracycline anticancer drugs, paclitaxel anticancer drugs, vinca alkaloid anticancer drugs, platinum anticancer drugs, and 5-fluorouracil, methotrexate, cyclophosphamide, temozolomide and pemetrexed.

[0015] Further optionally, the anthracycline anticancer drug is doxorubicin or epirubicin; the paclitaxel anticancer drug is paclitaxel or docetaxel; the vinca alkaloid anticancer drug is vinblastine, vincristine, vindesine or vinorelbine; the platinum anticancer drug is oxaliplatin or nedaplatin.

[0016] Optionally, the mass percentage of the photosensitizer is 2-5%; the mass percentage of the anti-tumor drug is 8%-25%.

[0017] Optionally, the mass percentage of ICG is 2-5%, and the mass percentage of DOX is 8%-25%.

[0018] Optionally, the overall size of the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite is 100-400 nm.

[0019] Further optionally, the upper limit of the particle size range of the self-oxygen supply targeted bionic core-membrane structure nanocomposite is selected from 400nm, 350nm, 300nm, 250nm, 200nm, 100nm, 120nm, and 150nm.

[0020] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite is dispersed in a solution such as deionized water, PBS, or physiological saline.

[0021] Optionally, the self-oxygen-supplying targeted bionic core-membrane structure nanocomposite has a particle size change of <95% within 7 days, <92% within 14 days, <90% within 21 days, <88% within 28 days, <85% within 35 days, <80% within 42 days, <75% within 49 days, and <70% within 56 days.

[0022] Optionally, the hollow MnO 2 The invention can be prepared by any one of the following methods: template etching method, coprecipitation method, precipitation method, hydrothermal reaction, solvent thermal reaction and ultrasonic synthesis method.

[0023] Optionally, when the hollow MnO is prepared by the template etching method 2 When the etching agent is selected from sodium carbonate, hydrofluoric acid, ammonium bifluoride, ammonium fluoride, tetrafluoromethane, buffered oxide etchant (BOE), CHF3, CH 2 F 2 , CHF 3 / CH 2 F2 , C 4 F 8 , C 5 F 8 , C 4 F 8 / C 5 F 8 Any one of .

[0024] Optionally, the hollow MnO 2 The centrifugal speed of the centrifugal washing is selected from 4000 to 14000g.

[0025] Further optionally, the centrifugation speed is selected from 14000g, 13000g, 12000g, 11000g, 10000g, 9000g, 4000g, 5000g, 6000g, 7000g, and 8000g.

[0026] Optionally, the nuclear membrane complex is prepared using a manual liposome extruder or an automatic liposome extruder.

[0027] Further optionally, the manual liposome extruder extrusion speed is 2-10 mL / s, and the extrusion speed is selected from 10 mL / s, 9 mL / s, 8 mL / s, 7 mL / s, 6 mL / s, 2 mL / s, 3 mL / s, 4 mL / s, 5 mL / s. The automatic liposome extruder extrusion force is 2000-6000 psi.

[0028] Further optionally, the upper limit of the extrusion speed is selected from 5000psi, 4500psi, 4000psi, 3500psi, 3000psi, and the lower limit is selected from 1000psi, 1500psi, 2000psi, 2500psi.

[0029] Optionally, the temperature control range of nuclear membrane complex extrusion is 4-45° C. Further optionally, the extrusion temperature is selected from 45° C., 42° C., 40° C., 37° C., 35° C., 32° C., 30° C., 27° C., 25° C., 22° C., 20° C., 5° C., 7° C., 10° C., 12° C., 15° C., 17° C.

[0030] The second object of the present invention is to provide a method for preparing the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite, which comprises the following steps:

[0031] S1. Preparation of photosensitizer-carrying bionic liposomes with targeting performance: Synthesizing photosensitizer-carrying bionic liposomes modified with tumor cell membrane proteins by co-extrusion of photosensitizer-carrying liposomes and tumor cell membrane proteins;

[0032] S2. Preparation of drug-loaded hollow MnO2 :SiO 2 As a template, prepare hollow MnO 2 ; The obtained hollow manganese dioxide is co-stirred with a hydrophobic therapeutic drug to achieve the loading of the hydrophobic drug in the hollow core;

[0033] S3. Preparation of biomimetic liposomes / drug-loaded hollow MnO 2 Composite: The biomimetic liposomes prepared in step S1 and the drug-loaded hollow MnO 2 The finished product is obtained by co-extrusion through a polycarbonate membrane, repeated extrusion for multiple times, and centrifugal freeze drying.

[0034] Optionally, the biomimetic liposome hydration solution in step S1 is selected from any one of deionized water, PBS buffer, Tris-HCl buffer, Tris buffer, physiological saline, 5% sucrose solution, and 5% glucose solution.

[0035] Optionally, the synthetic liposome loaded with photosensitizer is prepared by thin film hydration method, thin film ultrasonic dispersion method, reverse evaporation method or microemulsion ultrasonic dispersion method.

[0036] Optionally, the number of extrusions in the co-extrusion method in step S1 is between 20 and 60 times.

[0037] Further optionally, the number of extrusions is selected from 60 times, 55 times, 50 times, 45 times, 40 times, 20 times, 25 times, 30 times, and 35 times.

[0038] Optionally, the synthetic liposomes loaded with photosensitizer in step S1 are prepared by a thin film ultrasonic dispersion method, which comprises the following steps: dissolving phospholipid bilayer membrane, DSPE-PEG2000, cholesterol and photosensitizer in a molar ratio of 100:20:4:10 in a chloroform solution, mixing thoroughly, and then rotary evaporating at 40°C to form a film. After the film is formed, vacuumizing for 3 hours to completely evaporate the organic solvent; adding PBS to the round-bottom flask after the film is formed, hydrating under ultrasonic conditions at 60°C, and washing by centrifugation with deionized water to obtain the synthetic liposomes loaded with photosensitizer.

[0039] Further optionally, the drug-loaded hollow MnO 2 The monodispersed SiO 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 After continued stirring, MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite is placed in an etching solution to etch SiO 2The core is centrifuged, washed and dried to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with the drug, perform physical stirring, centrifugation, separation, and freeze drying at room temperature to obtain the drug-loaded hollow MnO 2 .

[0040] Further optionally, in step S2, monodisperse SiO 2 When the SiO 2 The stirring speed of the preparation is 100-700 rpm, the reaction time is 12-36 hours, and the reaction temperature is 25-60°C.

[0041] Further optionally, the ultrasonic conditions in step S2 include: ultrasonic power of 20 to 50 W / cm 2 , the ultrasound time is controlled at 0.5~6h.

[0042] Further optionally, in step S2, the hollow MnO 2 In the process, the drying method is any one of heating drying, heating vacuum drying, and freeze vacuum drying. When vacuum drying is adopted, the heating temperature can be selected from 60 to 300°C; the vacuum time can be selected from 3h to 72h; and the freezing temperature can be selected from -70 to -80°C.

[0043] Further optionally, in step S2, after preparing the drug-loaded hollow MnO 2 During the process, the speed of physical stirring is 100-800 rpm, and the stirring time is selected from 12-48 hours.

[0044] Further optionally, in step S2, when preparing the drug-loaded hollow MnO 2 During the process, that is, the centrifugal speed of the final product is selected from 4000 to 20000 rpm, and the centrifugal temperature is selected from 4 to 25°C.

[0045] The third purpose of the present invention is to provide a self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite for use in the preparation of drugs for treating cancer, wherein the complex is used for precise targeting and combined synergistic treatment of multiple tumors in the preparation of drugs for treating cancer.

[0046] Optionally, the cancer includes breast cancer, thyroid cancer, esophageal cancer, pancreatic cancer, lung cancer, kidney cancer, liver cancer, melanoma, etc.

[0047] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite has T1-weighted MRI imaging performance, and the complex can be used for accurate diagnosis and boundary identification of cancer in the preparation of drugs for treating cancer with the help of MRI imaging performance.

[0048] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite has fluorescence imaging performance, and the complex can be used for accurate diagnosis and boundary identification of cancer in the preparation of drugs for treating cancer by means of fluorescence imaging performance.

[0049] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite has an absorption peak at a wavelength of 808 nm, can generate ROS and thermal energy under irradiation, and has good photothermal and photodynamic properties. The complex is used for photothermal and photodynamic therapy of tumors in the preparation of drugs for treating cancer.

[0050] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite has homologous targeting properties.

[0051] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomplex is responsive to the tumor microenvironment and can generate oxygen in situ at the tumor site to improve tumor hypoxia.

[0052] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite carries chemotherapy drugs, and the complex is used for tumor chemotherapy in the preparation of drugs for treating cancer.

[0053] Optionally, the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite has good biosafety, and no obvious hemolytic reaction is observed.

[0054] The beneficial effects of this application include:

[0055] 1) In the present invention, cell membrane is used as a carrier, which not only has good biocompatibility, but also can promote the long circulation and targeted delivery of the nanoparticles in the core in vivo without considering the properties of the nanomaterials in the core.

[0056] 2) The self-oxygen-supplying targeted bionic core membrane structure nanocomposite provided by the present invention is composed of MnO 2 As the core, it has PH, H 2 O 2 and glutathione responsiveness, producing O in situ in the tumor 2 and Mn 2+ , giving the nanocomplex responsive oxygen production and MRI imaging properties, thereby achieving accurate diagnosis and enhancing the effect of combined therapy.

[0057] 3) The raw materials of the present invention are economical and readily available, the preparation method has mild conditions, has low requirements on equipment, operation, environment, etc., is easy to implement, and has good stability and reproducibility, and has the prospect of expanding production.

[0058] 4) Cell membrane biomimetic technology is a simple top-down method that uses the differences in protein expression on the surface of tumor cell membranes to specifically target homologous tumor cells, achieve precise drug targeting, and has higher biosafety. 2 It is an inorganic material that is responsive to the tumor microenvironment and has pH, H 2 O 2 and glutathione responsiveness, producing O 2 and Mn 2 + It can not only improve local hypoxia of tumors and enhance the therapeutic efficacy of tumors, but can also be used for MR contrast imaging to monitor tumor growth and the distribution and metabolism of drugs in the body. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1 This is a schematic diagram of the composition of the self-oxygen supply targeted bionic nuclear membrane structure nanocomposite obtained in Example 1;

[0060] Figure 2 TEM image of the self-oxygen supply targeted bionic nuclear membrane structure nanocomposite obtained in Example 1;

[0061] Figure 3 Schematic diagram of the in vitro oxygen production content of the self-oxygen supply targeted biomimetic nuclear membrane structure nanocomposite in Example 1;

[0062] Figure 4 This is an uptake diagram of the self-oxygen supply targeted bionic nuclear membrane structure nanocomplex in Example 1 in 4T1 tumor cells;

[0063] Figure 5 The in vitro magnetic resonance imaging of the self-oxygen-supplying targeted biomimetic nuclear membrane structure nanocomposite in Example 1;

[0064] Figure 6 This is a photothermal performance diagram of the self-oxygen supply targeted bionic nuclear membrane structure nanocomposite in Example 1 in vitro;

[0065] Figure 7 This is a singlet oxygen detection diagram of the self-oxygen supply targeted bionic nuclear membrane structure nanocomposite in Example 1;

[0066] Figure 8 This is a small animal fluorescence imaging image of the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite in Example 1.

[0067] Description of reference numerals:

[0068] 1. Doxorubicin; 2. Hollow manganese dioxide; 3. Indocyanine green; 4. 4T1 tumor cell membrane protein; 5. Phospholipid bilayer membrane. DETAILED DESCRIPTION

[0069] In order to have a clearer understanding of the technical features, purposes and beneficial effects of the present invention, the technical scheme of the present invention is now described in detail below in conjunction with specific embodiments. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. In the embodiments, each original reagent is commercially available, and the experimental scheme without specifying specific conditions is a conventional method and conventional conditions known in the art, or according to the conditions recommended by the manufacturer. The instruments and test conditions used in the embodiments are as follows:

[0070] The material morphology was observed on a JEOL-2100 transmission electron microscope under the test conditions of 200KV and 101μA.

[0071] Particle size distribution The particle size of the materials was tested on a Zetasizer Nano ZS dynamic light scattering particle size analyzer.

[0072] Surface protein markers were detected by SDS-PAGE electrophoresis on a Bio-Rad electrophoresis instrument.

[0073] Cytotoxicity test The MTT method was used to analyze the cytotoxicity of the materials on a UV-2102PC UV-visible spectrophotometer.

[0074] Magnetic Resonance Imaging Analysis Material imaging studies were conducted on a 3.0T magnetic resonance imager, with test conditions T1: TR = 650 ms, TE = 200 ms.

[0075] Example 1

[0076] The self-oxygenation targeted biomimetic nuclear membrane structure nanocomposite was synthesized according to the following steps:

[0077] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add PBS to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under ice bath conditions with a 400 nm polycarbonate film to obtain ICG-loaded bionic liposomes, wash with centrifugation, and store at 4°C.

[0078] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , continue stirring for 12h to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Heat at 60°C overnight to etch SiO 2 The core was centrifuged at 8000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 300 rpm at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0079] S3, 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL DOX-loaded hollow manganese dioxide were co-extruded through a 200 mm polycarbonate membrane in an ice bath, and the extrusion was repeated 20 times, followed by centrifugal freeze drying to obtain a nanocomposite product. Figure 1 shown.

[0080] Example 2

[0081] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add 5% sucrose to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under ice bath conditions with a 400 nm polycarbonate film to obtain ICG-loaded bionic liposomes, wash with centrifugation, and store by freeze-drying.

[0082] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring overnight, MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Heat at 60°C overnight to etch SiO 2 The core was centrifuged at 8000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO2 .

[0083] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL DOX-loaded hollow manganese dioxide, co-extrude through a 200 mm polycarbonate membrane in an ice bath, repeat the extrusion 20 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0084] Example 3

[0085] The self-oxygenated targeted biomimetic nuclear membrane structure nanocomposite was synthesized according to the following steps.

[0086] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder with a 400 nm polycarbonate membrane to obtain ICG-loaded bionic liposomes, wash with centrifugation, and store at 4°C.

[0087] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Heat at 60℃ for 24h to etch SiO 2 The core was centrifuged at 9000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge and separate to obtain drug-loaded hollow MnO 2 .

[0088] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL DOX-loaded hollow manganese dioxide, co-extrude through a 200 mm polycarbonate membrane in an ice bath, repeat the extrusion 20 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0089] Example 4

[0090] The self-oxygenated targeted biomimetic nuclear membrane structure nanocomposite was synthesized according to the following steps.

[0091] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder with a 400 nm polycarbonate membrane to obtain ICG-loaded bionic liposomes, wash with centrifugation, and store at 4°C.

[0092] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in hydrofluoric acid and stirred at room temperature for 3 h to etch SiO 2 The core was centrifuged at 7000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge and separate to obtain drug-loaded hollow MnO 2 .

[0093] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL DOX-loaded hollow manganese dioxide, co-extrude through a 200 mm polycarbonate membrane in an ice bath, repeat the extrusion 30 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0094] Example 5

[0095] The self-oxygenated targeted biomimetic nuclear membrane structure nanocomposite was synthesized according to the following steps.

[0096] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted MDA-MB-468 cell membrane proteins using a liposome extruder with a 400 nm polycarbonate film to obtain ICG-loaded bionic liposomes, wash with centrifugation, and store at 4°C.

[0097] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , continue stirring for 24h to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in hydrofluoric acid and stirred at room temperature for 3 h to etch SiO 2 The core was centrifuged at 7000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge and separate to obtain drug-loaded hollow MnO 2 .

[0098] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL DOX-loaded hollow manganese dioxide, co-extrude through a 200 mm polycarbonate membrane in an ice bath, repeat the extrusion 30 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0099] Example 6

[0100] The self-oxygenated targeted biomimetic nuclear membrane structure nanocomposite was synthesized according to the following steps.

[0101] S1. Preparation of Ce6-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and Ce6 in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained Ce6-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder with a 400nm polycarbonate film to obtain Ce6-loaded bionic liposomes, wash with centrifugation, and store at 4°C.

[0102] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in hydrofluoric acid and stirred at room temperature for 2 h to etch SiO 2 The core was centrifuged at 7000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge and separate to obtain drug-loaded hollow MnO 2 .

[0103] S3. Take 500 μL of 1 mg / mL Ce6 biomimetic liposomes and 500 μL of 2 mg / mL DOX hollow manganese dioxide and co-extrude them through a 200 mm polycarbonate membrane in an ice bath. After repeated extrusion for 30 times, centrifugal freeze-drying was performed to obtain a nanocomposite product.

[0104] Example 7

[0105] The self-oxygenated targeted biomimetic nuclear membrane structure nanocomposite was synthesized according to the following steps.

[0106] S1. Preparation of IR780-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and IR780 in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained IR780-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder with a 400 nm polycarbonate film to obtain IR780-loaded bionic liposomes, wash with centrifugation, and store at 4°C.

[0107] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in hydrofluoric acid and stirred at room temperature for 1 h to etch SiO 2 The core was centrifuged at 7000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge and separate to obtain drug-loaded hollow MnO 2 .

[0108] S3. Take 500 μL of 1 mg / mL IR780-loaded biomimetic liposomes and 500 μL of 1 mg / mL DOX-loaded hollow manganese dioxide, co-extrude through a 200 mm polycarbonate membrane in an ice bath, repeat the extrusion 30 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0109] Example 8

[0110] The self-oxygenated targeted biomimetic nuclear membrane structure nanocomposite was synthesized according to the following steps.

[0111] S1. Preparation of IR780-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and IR780 in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and perform rotary evaporation at 40°C to form a film. After film formation, evacuate the film for 4 hours to completely evaporate the organic solvent. Add PBS solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained IR780-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder with a 400 nm polycarbonate membrane to obtain IR780-loaded bionic liposomes, wash with centrifugation, and store at 4°C.

[0112] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in hydrofluoric acid and stirred at room temperature for 2 h to etch SiO 2 The core was centrifuged at 7000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge and separate to obtain drug-loaded hollow MnO 2 .

[0113] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL DOX-loaded hollow manganese dioxide, co-extrude through a 200 mm polycarbonate membrane in an ice bath, repeat the extrusion 20 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0114] Example 9

[0115] Preparation of ICG-loaded bionic liposomes: Phosphatidylcholine, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:5:10 were dissolved in chloroform solution and mixed thoroughly, then rotary evaporated at 40°C to form a film, and vacuum was applied for 3 hours after film formation to allow the organic solvent to evaporate completely; PBS was added to the round-bottom flask after film formation, and the film was hydrated under ultrasonic conditions at 55°C, and the ICG-loaded liposomes were obtained after centrifugal washing with deionized water; the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins were co-extruded with a liposome extruder under ice bath conditions using a 200 nm polycarbonate film to obtain the ICG-loaded bionic liposomes, which were washed by centrifugation and stored at 4°C.

[0116] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , and continued stirring overnight for 12 h to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Heat at 65°C overnight to etch SiO 2 The core was centrifuged at 7000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 400 rpm at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0117] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL DOX-loaded hollow manganese dioxide, co-extrude through a 200 mm polycarbonate membrane in an ice bath, repeat the extrusion 20 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0118] Example 10

[0119] Preparation of ICG-loaded bionic liposomes: Phosphatidylcholine, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 were dissolved in chloroform solution and mixed thoroughly, then rotary evaporated at 40°C to form a film, and vacuum was applied for 3 hours after film formation to allow the organic solvent to evaporate completely; PBS was added to the round-bottom flask after film formation, and the film was hydrated under ultrasonic conditions at 60°C, and the ICG-loaded liposomes were obtained after centrifugal washing with deionized water; the obtained ICG-loaded liposomes and the extracted MCF-7 cell membrane proteins were co-extruded with a liposome extruder under ice bath conditions using a 200 nm polycarbonate film to obtain the ICG-loaded bionic liposomes, which were washed by centrifugation and stored at 4°C.

[0120] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed with ethanol / water solution, centrifuged at room temperature, and KMnO added under ultrasonic conditions 4 , and continued stirring overnight for 12 h to obtain MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Heat at 60°C overnight to etch SiO 2The core was centrifuged at 8000 g, washed, and freeze-dried for 48 h to obtain the hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at 300 rpm at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0121] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 100 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0122] Embodiment 11

[0123] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 3 hours to completely evaporate the organic solvent; add PBS to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0124] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Etching SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0125] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude them through a 100 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0126] Example 12

[0127] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuum is applied for 3 hours to completely evaporate the organic solvent. PBS is added to the round-bottom flask after the film is formed, and the film is hydrated under ultrasonic conditions at 60°C. After centrifugation and washing with deionized water, ICG-loaded liposomes are obtained. The obtained ICG-loaded liposomes and the extracted AKR tumor cell membrane proteins are co-extruded using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, which are then centrifuged and washed, and stored at 4°C.

[0128] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Etching SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0129] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL DOX-loaded hollow manganese dioxide and co-extrude through a 100 mm polycarbonate membrane in an ice bath. Repeat the extrusion 20 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0130] Example 13

[0131] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 3 hours to completely evaporate the organic solvent; add PBS to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0132] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Etching SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0133] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0134] Embodiment 14

[0135] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:10 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 3 hours to completely evaporate the organic solvent; add 5% sucrose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0136] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Etching SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0137] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0138] Embodiment 15

[0139] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:5:20 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuum is applied for 3 hours to completely evaporate the organic solvent. Add 5% sucrose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0140] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring for 24h to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Etching SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0141] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0142] Example 16

[0143] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:5:20 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 4 hours to completely evaporate the organic solvent; add PBS solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0144] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring for 24h to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Etching SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0145] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0146] Embodiment 17

[0147] S1. Preparation of Ce6-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and Ce6 in a molar ratio of 100:20:5:20 in chloroform solution, mix thoroughly and perform rotary evaporation to form a film. After film formation, evacuate the film for 5 hours to completely evaporate the organic solvent. Add PBS solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained Ce6-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain Ce6-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0148] S2. Preparation of monodispersed SiO by sol-gel method 2Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring for 24h to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in hydrofluoric acid to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0149] S3. Take 500 μL of 1 mg / mL Ce6 biomimetic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0150] Embodiment 18

[0151] S1. Preparation of IR780-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and IR780 in a molar ratio of 100:20:5:20 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After film formation, evacuate the film for 5 hours to completely evaporate the organic solvent. Add PBS solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain IR780-loaded liposomes. Co-extrude the obtained IR780-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under ice bath conditions with a 400 nm polycarbonate film to obtain IR780-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0152] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring for 24h to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in hydrofluoric acid to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0153] S3. Take 500 μL of 2 mg / mL IR780-loaded biomimetic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0154] Embodiment 19

[0155] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 3 hours to completely evaporate the organic solvent; add 5% glucose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0156] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite is placed in hydrofluoric acid and stirred at room temperature to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0157] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0158] Embodiment 20

[0159] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 4 hours to completely evaporate the organic solvent; add PBS solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0160] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite is placed in hydrofluoric acid and stirred at room temperature to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0161] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0162] Embodiment 21

[0163] S1. Preparation of ICG-loaded bionic liposomes: Take a chloroform solution of lecithin, DSPE-PEG2000, cholesterol, and ICG-ODA in a molar ratio of 100:20:4:10, mix them thoroughly, and then rotary evaporate to form a film. After the film is formed, evacuate the solution for 3 hours to completely evaporate the organic solvent; add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0164] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite is placed in hydrofluoric acid and stirred at room temperature to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0165] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0166] Embodiment 22

[0167] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuum is applied for 3 hours to completely evaporate the organic solvent. Add 5% glucose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0168] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 , stirring at 60℃ to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0169] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0170] Embodiment 23

[0171] S1. Preparation of IR780-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and IR780 in a molar ratio of 100:20:4:10 in a chloroform solution, mix thoroughly, and then evaporate by rotary evaporation to form a film. After the film is formed, vacuum is applied for 3 hours to completely evaporate the organic solvent. Add 5% glucose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain IR780-loaded liposomes. Co-extrude the obtained IR780-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain IR780-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0172] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite is placed in hydrofluoric acid and stirred at room temperature to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0173] S3. Take 500 μL of 1 mg / mL IR780-loaded biomimetic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0174] Embodiment 24

[0175] S1. Preparation of Ce6-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and Ce6 in a molar ratio of 100:20:4:10 in chloroform solution, mix thoroughly and perform rotary evaporation to form a film. After film formation, evacuate the film for 3 hours to completely evaporate the organic solvent. Add PBS solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash by centrifugation with deionized water to obtain Ce6-loaded liposomes. Co-extrude the obtained Ce6-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain Ce6-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0176] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite is placed in hydrofluoric acid and stirred at room temperature to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0177] S3. Take 500 μL of 1 mg / mL Ce6 biomimetic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0178] Embodiment 25

[0179] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 4 hours to completely evaporate the organic solvent; add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0180] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions4 , continue stirring overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 Stir overnight at 60°C to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature for 24 h, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0181] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0182] Embodiment 26

[0183] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuum is applied for 3 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0184] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in a hydrofluoric acid solution and stirred at a low speed for 1 h to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0185] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude through a 200 mm polycarbonate membrane. Repeat the extrusion 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0186] Embodiment 27

[0187] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After the film is formed, vacuum is applied for 4 hours to completely evaporate the organic solvent. Add 5% sucrose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0188] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in a hydrofluoric acid solution and stirred at a low speed for 2 h to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0189] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0190] Embodiment 28

[0191] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuum is applied for 5 hours to completely evaporate the organic solvent. Add 5% glucose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0192] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 3 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0193] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0194] Embodiment 29

[0195] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After film formation, evacuate the film for 6 hours to completely evaporate the organic solvent. Add PBS solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0196] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in a hydrofluoric acid solution and stirred at a low speed for 3 h to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0197] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0198] Embodiment 30

[0199] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuumize for 3 hours to completely evaporate the organic solvent; add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0200] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in a hydrofluoric acid solution and shaken at a low speed for 1 h to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO2 .

[0201] S3. Take 500 μL of 1 mg / mL ICG-loaded biomimetic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 100 mm polycarbonate membrane. Repeat the extrusion for 30 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0202] Embodiment 31

[0203] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuum is applied for 3 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0204] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in a hydrofluoric acid solution and shaken at a low speed for 2 h to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0205] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0206] Embodiment 32

[0207] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:15 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, vacuumize for 4 hours to completely evaporate the organic solvent; add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes; co-extrude the obtained ICG-loaded liposomes and the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0208] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0209] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude through a 200 mm polycarbonate membrane. Repeat the extrusion for 25 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0210] Embodiment 33

[0211] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:20 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After film formation, evacuate the film for 6 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 55°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0212] S2. Preparation of monodispersed SiO by sol-gel method2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0213] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0214] Embodiment 34

[0215] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:20 in chloroform solution, mix thoroughly, and then evaporate by rotary evaporation to form a film. After the film is formed, vacuum is applied for 5 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0216] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 , continue stirring at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0217] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0218] Embodiment 35

[0219] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:20 in chloroform solution, mix thoroughly, and then evaporate by rotary evaporation to form a film. After the film is formed, vacuum is applied for 5 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0220] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 30 min, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with paclitaxel, physically stir at room temperature, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0221] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0222] Embodiment 36

[0223] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:20 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After the film is formed, vacuum is applied for 5 hours to completely evaporate the organic solvent. Add 5% glucose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0224] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mixed with paclitaxel, physically stirred under ice bath conditions, centrifuged, separated, and freeze-dried to obtain drug-loaded hollow MnO 2 .

[0225] S3. Take 500 μL of 2 mg / mL ICG-loaded bionic liposomes and 500 μL of 2 mg / mL manganese oxide and co-extrude through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0226] Embodiment 37

[0227] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:6:20 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After the film is formed, vacuum is applied for 6 hours to completely evaporate the organic solvent. Add 5% sucrose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0228] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mixed with paclitaxel, physically stirred under ice bath conditions, centrifuged, separated, and freeze-dried to obtain drug-loaded hollow MnO 2 .

[0229] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion for 30 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0230] Embodiment 38

[0231] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:5:10 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After the film is formed, vacuum is applied for 6 hours to completely evaporate the organic solvent. Add 5% sucrose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0232] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO2 Mixed with paclitaxel, physically stirred under ice bath conditions, centrifuged, separated, and freeze-dried to obtain drug-loaded hollow MnO 2 .

[0233] S3. Take 500 μL of 1 mg / mL ICG-loaded biomimetic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 100 mm polycarbonate membrane. Repeat the extrusion for 30 times, and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0234] Embodiment 39

[0235] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:5:15 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After film formation, evacuate the film for 6 hours to completely evaporate the organic solvent. Add 5% sucrose solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store by freeze-drying.

[0236] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mixed with paclitaxel, physically stirred under ice bath conditions, centrifuged, separated, and freeze-dried to obtain drug-loaded hollow MnO 2 .

[0237] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 100 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0238] Embodiment 40

[0239] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:5:20 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After film formation, evacuate the film for 6 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0240] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir under ice bath conditions, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0241] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0242] Embodiment 41

[0243] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:15 in chloroform solution, mix thoroughly, and perform rotary evaporation to form a film. After film formation, evacuate the film for 6 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 400 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0244] S2. Preparation of monodispersed SiO by sol-gel method2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir under ice bath conditions, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0245] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 200 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0246] Embodiment 42

[0247] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:20 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, evacuate the film for 5 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0248] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in a hydrofluoric acid solution and shaken at a low speed for 3 h to etch SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2Mix with DOX, physically stir under ice bath conditions, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0249] S3. Take 500 μL of 1 mg / mL ICG-loaded bionic liposomes and 500 μL of 1 mg / mL manganese oxide and co-extrude them through a 100 mm polycarbonate membrane. Repeat the extrusion 20 times and then centrifuge and freeze-dry to obtain a nanocomposite product.

[0250] Comparative Example 1

[0251] S1. Preparation of ICG-loaded common liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:20 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After the film is formed, vacuumize for 5 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, wash with deionized water by centrifugation to obtain ICG-loaded liposomes, and store at 4°C.

[0252] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, washed, centrifuged, and KMnO added under ultrasonic conditions 4 After continuing ultrasonication for 1 h, stirring was continued at room temperature overnight to prepare MnO 2 Encapsulated SiO 2 Nanocomposite; the obtained MnO 2 Encapsulated SiO 2 The nanocomposite was placed in Na 2 CO 3 In the solution, SiO 2 The core was centrifuged, separated and freeze-dried to obtain hollow MnO 2 ; The hollow MnO 2 Mix with DOX, physically stir under ice bath conditions, centrifuge, separate, and freeze-dry to obtain drug-loaded hollow MnO 2 .

[0253] S3, take 500 μL of 1 mg / mL ICG-loaded biomimetic liposomes and 500 μL of 1 mg / mL drug-loaded hollow MnO 2 The nanocomposite product was prepared by co-extrusion through a 200 mm polycarbonate film, repeated extrusion for 20 times, and centrifugal freeze-drying.

[0254] The nanocomposite product prepared in this comparative example is a non-bionic modified nuclear membrane nanocomposite (HMD-IL).

[0255] Comparative Example 2

[0256] S1. Preparation of ICG-loaded bionic liposomes: dissolve lecithin, DSPE-PEG2000, cholesterol and ICG-ODA in a molar ratio of 100:20:4:20 in chloroform solution, mix thoroughly, and then rotary evaporate to form a film. After film formation, evacuate the film for 5 hours to completely evaporate the organic solvent. Add Tris solution to the round-bottom flask after film formation, hydrate under ultrasonic conditions at 60°C, and wash with deionized water by centrifugation to obtain ICG-loaded liposomes. Co-extrude the obtained ICG-loaded liposomes with the extracted 4T1 tumor cell membrane proteins using a liposome extruder under 200 nm polycarbonate membrane conditions to obtain ICG-loaded bionic liposomes, wash by centrifugation, and store at 4°C.

[0257] S2. Preparation of monodispersed SiO by sol-gel method 2 Nanospheres, the obtained SiO 2 CTAB solution, ammonia water and BTEB were added to the nanosphere solution and stirred continuously to obtain solid SiO 2 The core-shell structured composite was placed in Na 2 CO 3 The template was removed from the solution, and the hollow mesoporous SiO was obtained by centrifugation, separation, and freeze-drying. 2 ; The hollow mesoporous SiO 2 The DOX-loaded hollow mesoporous SiO 2 .

[0258] S3, take 500 μL of 1 mg / mL ICG-loaded biomimetic liposomes and 500 μL of 1 mg / mL DOX-loaded hollow mesoporous SiO 2 The nanocomposite product was prepared by co-extrusion through a 200 mm polycarbonate film, repeated extrusion for 20 times, and centrifugal freeze-drying.

[0259] The nanocomposite product prepared in this comparative example is hollow mesoporous SiO 2 Drug-loaded nuclear membrane nanocomplex (HSD-I-BL).

[0260] Experimental Example 1

[0261] Structural characterization of self-oxygenation targeted biomimetic nuclear membrane structure nanocomposite

[0262] Structural characterization of each complex prepared in Example 1

[0263] Characterization method: Transmission electron microscopy Scanning instrument: FEITecnai F20

[0264] Figure 2 The TEM image of the product obtained in Example 1 is given.

[0265] The same structural characterization was performed on each complex prepared in other embodiments of the present invention, proving that the method of the present invention can indeed be used to obtain a self-oxygen-supplying targeted bionic core-membrane structured nanocomposite.

[0266] Experimental Example 2

[0267] Experimental study on oxygen production of self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite

[0268] The self-oxygen-supplying targeted biomimetic core membrane structure nanocomposite (HMD-I-BL) obtained in Example 1 and the hollow mesoporous SiO 2 Drug-loaded nuclear membrane nanocomplex (HSD-I-BL) was added to a solution containing hydrogen peroxide (10 mM H 2 O 2 ) and glutathione (10 mM GSH) in aqueous solution to simulate the responsive oxygen production of the nanocomplex in the in vitro tumor microenvironment. The nanocomplex was irradiated with 808 nm laser for 5 min (1 W / cm 2 ), measure the oxygen content in the solution. Figure 3 shown.

[0269] This result shows that hollow mesoporous SiO 2 No obvious oxygen production was observed in vitro for the drug-loaded nuclear membrane nanocomplex, and the obtained self-oxygen-supplying targeted bionic nuclear membrane structure nanocomplex had good in vitro oxygen production capacity under laser irradiation, and was used to improve tumor hypoxia in situ.

[0270] Experimental Example 3

[0271] Targeted experiment of self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite

[0272] 5000 4T1 breast cancer cells were seeded in 6-well plates at 37°C with 5% CO. 2 After overnight incubation, the self-oxygenation targeted bionic nuclear membrane nanocomposite (HMD-I-BL) prepared in Example 1 and the non-bionic modified nuclear membrane nanocomposite (HMD-IL) obtained in Comparative Example 1 were added at a dosage of 20 μg / mL ICG, and after co-incubation for 2 hours, the cells were washed with PBS and fixed with 4% paraformaldehyde. The uptake of the complex by 4T1 cells was observed using a laser confocal microscope. Figure 4 shown.

[0273] The obtained self-oxygen-supplying targeted bionic nuclear membrane structure nanocomplex has a significantly higher uptake in 4T1 cells than the non-bionic modified nanocomplex, has a good targeting effect, and is used for tumor targeted drug delivery.

[0274] Experimental Example 4

[0275] In vitro magnetic resonance imaging performance of self-oxygenated targeted biomimetic nuclear membrane structure nanocomposite

[0276] Example 1 is a typical example, and its magnetic resonance imaging is shown as follows: Figure 5 It can be seen that when the surrounding water phase environment is black, Example 1 presents a concentration-dependent bright signal (MRI T1 contrast enhancement), indicating that the sample self-oxygenation targeted bionic nuclear membrane structure nanocomposite has obvious T1-weighted magnetic resonance imaging function.

[0277] Experimental Example 5

[0278] In vitro photothermal performance of self-oxygenating targeted biomimetic nuclear membrane structure nanocomposite

[0279] The self-oxygenation targeted biomimetic nuclear membrane nanocomposite prepared in Example 1 with a dosage of 20 μg / mL ICG was dissolved in deionized water and irradiated with an 808 nm laser for 5 min. The temperature change of the solution under laser irradiation was observed with a near-infrared thermal imager. Figure 6 shown.

[0280] The obtained self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite has an obvious warming effect under laser irradiation, and the warming effect is similar to that of free ICG at the same concentration, indicating that the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite has good photothermal properties and can be used for tumor photothermal therapy.

[0281] Experimental Example 6

[0282] In vitro self-oxygenation targeted biomimetic nuclear membrane structure nanocomposite 1 O 2 Generate Assessment

[0283] Take 20 μg / mL ICG prepared in Example 1 and dissolve it in a solution containing H 2 O 2 The solution was irradiated with 808 nm laser for 5 min and the absorbance changes of the solution at different time points were observed by UV spectrophotometer. Figure 7 shown.

[0284] The absorbance of the obtained self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite under laser irradiation decreased significantly, indicating that the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite can effectively produce 1 O 2 , used for photodynamic therapy of tumors.

[0285] Experimental Example 7

[0286] Small animal fluorescence imaging of self-oxygenated targeted biomimetic nuclear membrane structure nanocomplex

[0287] The self-oxygenating targeted biomimetic nuclear membrane nanocomposite prepared in Example 1 at a concentration of 20 μg / mL ICG was dissolved in deionized water and injected into mice via the tail vein. The change in fluorescence intensity was observed by a small animal in vivo imaging device. Figure 8 shown.

[0288] The obtained self-oxygen-supplying targeted bionic nuclear membrane structure nanocomplex is gradually enriched in the tumor site, and the concentration is significantly higher than that of the non-bionic modified complex, indicating that the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomplex has good targeting properties and can be used for precise targeted treatment of tumors.

[0289] Although the disclosure is disclosed as above, the protection scope of the disclosure is not limited thereto. Those skilled in the art can make various changes and modifications without departing from the spirit and scope of the disclosure, and these changes and modifications will fall within the protection scope of the present invention.

Claims

1. A method for preparing a self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite, characterized in that: The following steps are involved: S1. Preparation of photosensitizer-loaded bionic liposomes with targeting performance: dissolving phospholipid bilayer membrane, DSPE-PEG2000, cholesterol and photosensitizer in a molar ratio of 100:20:4:10 in chloroform solution, mixing thoroughly, and performing rotary evaporation at 40°C to form a film. After film formation, vacuumizing for 3 hours to completely evaporate the organic solvent, adding PBS to the round-bottom flask after film formation, hydrating under ultrasonic conditions at 60°C, and washing with deionized water by centrifugation to obtain photosensitizer-loaded liposomes. Co-extrude the obtained photosensitizer-loaded liposomes with tumor membrane proteins through a polycarbonate membrane. After repeated extrusion for multiple times, photosensitizer-loaded bionic liposomes are obtained, wherein the tumor membrane protein is 4T1 tumor membrane protein. S2. Preparation of drug-loaded hollow MnO2: monodisperse SiO2 nanospheres were prepared by sol-gel method, washed with ethanol / water solution, centrifuged at room temperature, KMnO4 was added under ultrasonic conditions, and stirred continuously to obtain SiO2 nanocomposites wrapped with MnO2; the obtained SiO2 nanocomposites wrapped with MnO2 were placed in an etching solution to etch the SiO2 core, and hollow MnO2 was obtained after centrifugation, washing, and drying; the hollow MnO2 was mixed with the drug doxorubicin, and physically stirred, centrifuged, separated, and freeze-dried at room temperature to obtain drug-loaded hollow MnO2; S3. Preparation of bionic liposome / drug-loaded hollow MnO2 complex: co-extrude the bionic liposome prepared in step S1 and the drug-loaded hollow MnO2 prepared in step S2 through a polycarbonate membrane, repeatedly extrude for multiple times, and then centrifuge and freeze-dry to obtain a finished photosensitizer-loaded bionic liposome / drug-loaded hollow MnO2 complex, i.e., photosensitizer-loaded bionic liposome / drug-loaded hollow MnO2 complex.

2. The preparation method according to claim 1, characterized in that: The bionic lipid membrane contains a photosensitizer, and the photosensitizer is selected from at least one of Ce6, ICG-ODA, ICG-NH2, ICG-COOH, ICG-NHS, ICG-MAL, ICG-SH, ICG-N3, ICG-ALK, ICG-Biotin, IR780, IR783 and IR808.

3. The preparation method according to claim 1, characterized in that: The phospholipid bilayer membrane includes lecithin, hydrogenated soybean lecithin, hydrogenated egg yolk lecithin, dipalmitoyl phosphatidylethanol, dipalmitoyl phosphatidylcholine, dioleoyl phosphatidylethanolamine, polyethylene glycol-distearoyl phosphatidylethanolamine, 1,2-dipalmitoyl-sn-glyceryl-3-phosphatidic acid glyceryl-sodium salt, 1,2-distearoyl-sn-glyceryl-3-phosphatidylcholine, 1,2-dipalmitoyl-sn-glyceryl-3-phosphatidic acid-sodium salt and 1,2-dipalmitoyl-sn-glyceryl-3-phosphatidylcholine.

4. Use of the self-oxygen-supplying targeted bionic nuclear membrane structure nanocomposite prepared by the preparation method according to any one of claims 1 to 3 in the preparation of a drug for treating breast cancer.